IV Post

Atlanta, Georgia - An April 10, 2009 article appearing on Salon.com inaccurately represents the Centers for Disease Control and Prevention’s (CDC) 2004 public health response to a request from the Washington D.C. Department of Health for assistance concerning lead in water in District of Columbia neighborhoods (Blood Lead Levels in Residents of Homes with Elevated Lead in Tap Water - District of Columbia, 2004 MMWR Dispatch Vol. 53., March 30, 2004).

Washington, DC - The U.S. Food and Drug Administration today announced that it had obtained a permanent injunction barring Neilgen Pharmaceuticals Inc. of Westminster, Md., its parent company, Advent Pharmaceuticals, Inc. (Advent), of East Windsor, N.J., and two of their officers, Bharat Patel and Pragna Patel, from manufacturing and distributing any unapproved, adulterated or misbranded drugs.

Washington, DC - The U.S Food and Drug Administration today amended its March 30, 2009, action warning manufacturers to stop the production and distribution of certain unapproved prescription opioids, to allow the continued marketing and distribution of one particular type of opioid - a high concentrate morphine sulfate oral solution - on an interim basis.

Atlanta, Georgia - The incidence of the most common foodborne illnesses has changed very little over the past three years, according to a 10-state report released Thursday by the Centers for Disease Control and Prevention.  

Washington, DC -  Genentech, the manufacturer of the psoriasis drug Raptiva (efalizumab), announced that it has begun a voluntary, phased withdrawal of the product from the U.S. market. The company is taking this action because of a potential risk to patients of developing progressive multifocal leukoencephalopathy (PML), a rare, serious, progressive neurologic disease caused by a virus that affects the central nervous system.

Washington, DC - The FDA today announced that manufacturers of 25 types of medical devices marketed prior to 1976 must submit safety and effectiveness information to the agency so that it may evaluate the risk level for each device type. Devices found by the FDA to be of high risk to consumers will be required to undergo the agency’s most stringent premarket review process.